TME Pharma N.V. (EPA:ALTME)

Market Cap	10.28M
Revenue (ttm)	19.00K
Net Income (ttm)	-5.72M
Shares Out	94.12M
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	426,576
Average Volume	1,083,717
Open	0.1100
Previous Close	0.1092
Day's Range	0.1072 - 0.1100
52-Week Range	0.0600 - 0.1800
Beta	1.49
RSI	52.59
Earnings Date	Apr 23, 2025

About United States Steel

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2a clinical trial for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 12
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALTME

Financial Performance

In 2024, TME Pharma's revenue was 19,000, an increase of 11.76% compared to the previous year's 17,000. Losses were -5.72 million, -15.05% less than in 2023.